



ASX Release

## **RESIGNATION OF DIRECTOR**

**Melbourne, Australia; 1 August 2016:**

Jayex Healthcare Limited (ASX:JHL) (**JHL** or **Company**) advises that Mr John Allinson has tendered his resignation as Director of the Company. Mr Allinson has been part of the Jayex Group since 2006 in both executive and non-executive roles during this time.

Since listing in late 2015, JHL has undergone a process of integrating its businesses and realigning it to support global product channels. As JHL moves from commercialisation to deployment of its technologies it has started a process of adding new non-executive Directors which will assist the Company in its goals.

The Board will release more information about proposed changes and supply a trading update shortly and in the meantime wishes to thank Mr Allinson for his effort and expertise over this period and wishes him well in his future endeavours.

### **Contacts for further information:**

Executive Chairman  
Michael Boyd  
0447 600 888

Company Secretary  
Melanie Leydin  
0417 663 119

---

**About Jayex Healthcare Limited - [www.jayexhealthcare.com.au](http://www.jayexhealthcare.com.au)**

Jayex Healthcare is a leading provider in the United Kingdom and Australia of integrated healthcare services delivery platforms, incorporating the Company's four interconnected and proprietary technologies, being:

- the *Enlighten* patient workflow platform;
- the *Appointuit* patient engagement solution;
- the *Pharmacy Delivery 2 U* prescription delivery service ; and
- the *BluePoint*<sup>®</sup> remote pharmacy prescription processing and dispensing terminal.

Jayex offers 24/7, online, interconnected 'end-to-end' and 'state-of-the-art' healthcare service delivery platforms for:

- Patients – particularly the “time-poor”, the elderly and chronically ill who would likely benefit from better quality and more convenient healthcare services; and
- GPs/Healthcare professionals, clinics, pharmacies and hospitals – particularly those who want to deliver better healthcare services and enhanced patient well-being, more efficiently and at a lower cost, while at the same time, having the potential to increase their productivity, efficiency and profitability.

The Jayex technologies are designed to meet the demands and expectations of patients, GPs, AHPs, clinics, pharmacies and hospitals in today's market, and has the versatility and flexibility to accommodate future demands.

# Appendix 3Z

## Final Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Jayex Healthcare Limited</b>
<b>ABN</b>	<b>15 119 122 477</b>

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of director</b>	JOHN ALLINSON
<b>Date of last notice</b>	17 December 2015
<b>Date that director ceased to be director</b>	29 July 2016

### Part 1 – Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Number &amp; class of securities</b>
75,000 fully paid ordinary shares

+ See chapter 19 for defined terms.

## Appendix 3Z

### Final Director's Interest Notice

---

#### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b>	<b>Number &amp; class of securities</b>
Note: Provide details of the circumstances giving rise to the relevant interest	Nil

#### Part 3 – Director's interests in contracts

<b>Detail of contract</b>	Nil
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>No. and class of securities to which interest relates</b>	N/A

---

+ See chapter 19 for defined terms.